Sun Pharma Secures Interim Court Order on URSOCOL

The Bombay High Court has given an interim injunction to Sun Pharma Laboratories Limited, which will stop Rambo Lifesciences Pvt. Ltd. and their associates to use the trademarks URSOCAL and URSOCAL-300 as it is stated that these marks are of the deceptive similarity to Sun Pharma’s registered liver drug brand URSOCOL.

Sun Pharma filed the suit stating that Rambo Lifesciences has come up with these products and promoted these in such a way that confusion is likely to be caused in the minds of the doctors, chemists, and patients. Indeed, according to the order dated 20 August 2025, Justice Arif S Doctor endorsed the view of Sun Pharma and pointed out that the issue of confusion of pharmaceutical products is very alarming and hence the reaction of the judiciary is necessarily quick.

The Court at this instance prohibited Rambo Lifesciences, its promoters, proprietors Dr. Meera Jadhav, directors, partners, affiliates, sister/group companies, employees, distributors, stockists, super-stockists, e-commerce and warehouse aggregators, retailers, franchisees, licensees, importers, exporters, custodians, and all other related entities from trespassing upon Sun Pharma’s rights.

Also Read: AiMeD Hails Govt's Move on New GST Regime Transition

Previously, on 16 July 2025, the Court gave a wide-ranging powers to the Court Receiver to seize infringing goods, packaging materials, and documents. The order was carried out on 6 August 2025, and the Receiver submitted Report No. 371 of 2025.

The Court gave the adjournment, in this case, till 29 August 2025 as the service on Defendant No. 1 was incomplete, and thus, the interim relief in favor of Sun Pharma, which will operate up to the time of the final adjudication, shall be maintained to ensure the protection of the established brand URSOCOL.